Monthly Archives: February 2020

#V3PODCAST Episode 5: Rare Disease Day 2020

Host Dr. Anne Arvizu and Guest Dan Donovan

This special topical episode is focused and dedicated to patients around the world who are suffering with a rare disorder or rare disease. 

Dan has spent nearly three decades in the pharmaceutical industry on both the industry and service sides of the business – first with Pfizer then creating Envision Pharma, which was acquired by United BioSource Corporation. Dan’s introduction to the world of rare disease began in 2011 when he was appointed to the Board of Directors and later as Chief Business Officer of Cancer Prevention Pharmaceuticals. Dan is the primary visionary behind rareLife solutions.

Dan’s experiences and observations have led him to believe that there is a better, smarter way to engage all rare disease stakeholders and accelerate disease understanding and treatment success. He believes the power of collaboration is the linchpin to this fundamental change.

In this episode, Anne opens the show defining rare disease. A rare disease is a condition that affects fewer than 200,000 people, whereas Europe defines it as something that affects less than 1 in 2,000 people. Drug companies have not been interested in developing treatments for rare diseases; there just wasn’t the incentive. The drug companies would not be able to sustain the costs involved in developing medicine.

Dan gives his take on the importance of patient centricity in rare disease drug development. Patients have to educate their physicians because they typically know more about it than their doctors do. Patients can help develop these products in a smarter way than the drug companies could do alone.

When Dan first started working in the business, patients had little input in rare disease drug development. In the past three years, it has taken off. Now there is even a role called the chief of patient relations.

Then, Dan speaks about publications for rare diseases. These publications should differ from most medical publications. These publications should have open and free access to the public and include patients and advocates as authors on the papers.

The patient journey is not in typical medical literature. Dan sat with a patient who had a rare disease. They looked at the psycho-social elements of the disease and the impact on their family. This woman has to see about ten doctors a year; there are substantial cost implications on this. Eventually, they were able to share this patient’s journey in a publication.

Later, Dan talks about ensuring patient-centricity happens. Pharmaceutical is a highly regulated industry. Anything that suggests that companies are doing direct-to-patient promotion will scare them – it comes with huge fines. Historically, pharmaceutical companies take a long time to make changes.

Other Resources:

For medical affairs consulting, visit: https://rxercommunications.com/

For more about Anne, visit: https://annearvizu.com/

For more information about ACMA to become board certified in Medical Affairs visit: https://training.medicalaffairsspecialist.org/affiliate_page.aspx?unm=anne.aflt.arvizu

To listen to other podcasts on the Pharmacy Podcast Nation, our flagship home on the Pharmacy Podcast Network, subscribe on iTunes or visit: http://pharmacypodcast.com/

 
In this Episode:

  • About rare disease [ 1:50 ]
  • Why patient-centricity is critical in rare disease drug development [ 14:00 ]
  • Different rare disease events [ 21:10 ]
  • Publications for rare diseases [ 21:50 ]
  • Dan gives a patient example on publications for rare diseases [ 24:35 ]
  • How to ensure patient-centricity happens [ 28:10 ]
  • About rareLife solutions [ 30:35 ]

Quotables:

  • “Patients with rare disease go years and sometimes decades without receiving a proper diagnosis.” -Anne Arvizu
  • “1 in 10 Americans live with a rare disease and over 30 million people are living with a serious or life threatening lifelong illness that may have little more than symptomatic care and might not truly work.” -Anne Arvizu
  •  “Of over 7,000 rare diseases, there are only 450 drugs that are approved.” -Dan Donovan
  • “HCPs need to recognize that patients have become major experts on their rare disease.” -Anne Arvizu
  • “1,200 companies are researching 1,900 rare diseases right now.” -Dan Donovan
  • “How do you go looking for what you don’t know?” -Anne Arvizu
  • “There is no reason patients can’t be authors on medical publications.” -Dan Donovan

Links Mentioned: 

#V3PODCAST Episode 4: Should Pharma Sales Reps Answer Off-Label Use Questions?

Welcome back to the #V3Podcast.

This is The Vision, the Voice & the Value of Medical Affairs with Host, Dr. Anne Arvizu and Guest, Dr. Darshan Kulkarni.

Dr. Darshan Kulkarni is the Principal Attorney of the Kulkarni Law Firm and focuses his practice on helping FDA regulated companies successfully bring their products to market. He has over 20 years of experience in providing legal, medical, and regulatory services. Darshan has served as a pharmacist for over a decade – making him uniquely well-positioned to help clients through all stages of the development process. He advises clients on issues varying from FDA regulatory strategy, clinical trial negotiations, manufacturing audits, FDA compliant promotional and non-promotional review, FDA responses, to genericization and other interdependent processes.

In this episode, Anne opens the show explaining the term “unlabeled use.” In the United States, doctors use this all the time. They aren’t going to stop prescribing medicine if a drug will be beneficial to a patient. Darshan poses the question: is label and labeling the same thing? The goal of the FDA is to make sure the products are safe and not misbranded. The label is what is on the bottle. Labeling is anything that goes with the bottle. The term “goes with” is exceptionally broadly defined. Your sales materials can be considered labeling. If your sales rep speaks off label, that’s still part of the labeling of the bottle.

In the early 2000s, the FDA started going after companies about how medical affairs people were going off-label and acting as supercharged salespeople. The industry said that wasn’t true. The medical affairs, people are having a scientific conversation. There are categories of information that are not subject to censorship – such as a political speech. You can’t shut down political speech just because you do not like what they are saying. However, you can shut down two scientists because you do not like what they are saying. The FDA went to court with the pharma companies and lost the first case.

Every so often, people ask why the FDA won’t stop doctors from prescribing off label. The FDA has no jurisdiction over doctors. Prescribing is entirely legal, but off label marketing is not okay. All of the top fines that companies pay are from off label marketing. IMS Health Inc. collected data from people and gave the data to pharma companies. The state of Vermont said they were not able to sell the data because the companies would target the doctors too much, and it might raise the cost of prescribing. The Supreme Court asked: is it truthful and not misleading? Vermont said yes, but there was a cost to it. The Supreme Court said you couldn’t stop people from saying something simply because there will be a cost to it.

So what constitutes truthful and not misleading? To claim the FDA, you need randomized controlled studies – substantial evidence. If you want to make health economics claims, it does not require significant evidence. No one knows the difference between truthful and not misleading. Another case came up: United States v. Caronia. Ex-Orphan Medical sales rep Alfred Caronia successfully argued to a court that the First Amendment gives him a right to promote drugs for uses not approved by the FDA. The critical thing to look at is the role a person will play in a particular context – are they playing a salesperson or a physician?

Stay tuned to hear Dr. Darshan Kulkarni explain why we need medical affairs, the future of our industry, and why the industry is pushing back against the FDA.

Please follow the show so you don’t miss an episode. And if you like what you hear, please tag and or follow @annearvizu and share on social media with the hashtag #V3Podcast and #medicalaffairs

If you need more information regarding achieving value in medical affairs departments or learning more about Dr. Anne Arvizu then please visit the RxER Communications website here.

This show is being produced by the Pharmacy Podcast Network and is partner-sponsored by The Accreditation Council for Medical Affairs (ACMA) to help better serve the next generation of medical affairs leadership and adding value by supporting the medical experts and compliance leaders in our industry. You can find out more about ACMA here.

In this Episode:

  • About unlabeled uses [ 2:50 ]
  • About Dr. Kulkarni [ 5:30 ]
  • The difference between label and labeling [ 9:30 ]
  • Cases from the FDA [ 12:50 ]
  • Misbranding [ 17:45 ]
  • Presenting new data [ 20:50 ]
  • IMS Health Inc. v. Sorrell [ 22:50 ]
  • United States v. Caronia [ 27:00 ]
  • Sales reps can speak off label [ 40:00 ]
  • Why keep medical affairs? [ 43:30 ]
  • The future of our industry [ 50:00 ]
  • About guidance documents [ 53:00 ]

Quotes:

  • “At this moment, a sales rep can speak off label – there’s nothing to stop them.” -Dr. Darshan Kulkarni
  • “There’s a strong line between commercial and medical affairs.” -Anne Arvizu
  • “I don’t see big pharma changing.” -Dr. Darshan Kulkarni
  • “I shouldn’t be limited whether I’m in a company or out of a company to state what I feel.” -Anne Arvizu
  • “No one knows what truthful not misleading means.” -Dr. Darshan Kulkarni

Links Mentioned: 

Insert WordPress Content